Loading…
Uses human-genetics research to find precision drug targets; lead programs target Pompe disease and kidney disease.
Uses human-genetics research to find precision drug targets; lead programs target Pompe disease and kidney disease.
Has no approved medicine, so it lives on money raised from investors and on payments from partners, such as upfront and milestone fees, rather than product sales. Sales would start only if a drug is approved and launched. Its genetics-based list of drug targets is the asset it hopes to turn into several medicines.
Moat: narrow (data, IP / patents). A large genetics/target-discovery data engine underpins its pipeline selection process.
Headquarters: South San Francisco, California, US · Founded: 2019 · Employees: 141
Size Maze Therapeutics (MAZE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.90B, the 1831st largest of 3,117 United States companies the cockpit tracks. Shares closed at $34.19 on 6 Nov 2026.
Performance Over six months the shares gained 29.2%, against -8.7% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 700.0% over the last twelve months (peer median +10.9%); the operating margin is -728.1% (peer median 17.3%).
Valuation It trades at 77.4× enterprise value to sales against a peer median of 4.8× (most expensive of 21).
Capital Return on invested capital runs 127.0 points below its cost of capital (14.7% WACC).
Short interest Short interest is 13.6% of the free float (15 Oct 2026).
Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $20.0M | $0 | $168M | $0 | $0 |
| Revenue growth | — | -100% | — | — | — |
| Gross profit | $18.1M | -$2.40M | $164M | -$4.09M | -$3.82M |
| EBITDA | -$144M | -$140M | $60.9M | -$94.5M | -$107M |
| Net income | -$134M | -$131M | $18.4M | -$100M | -$115M |
| Free cash flow | -$107M | -$113M | $74.8M | -$87.3M | -$101M |
| Capital expenditure | $302,000 | $794,000 | $1.15M | $441,000 | $1.97M |
| Total debt | $60.4M | $23.3M | $26.6M | $49.6M | $32.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Maze Therapeutics MAZE | $1.90B | +29% | +700% | -728% | 77.4× | n/a |
| Regeneron Pharmaceuticals REGN | $93.5B | +27% | +19% | 30% | 5.2× | -2.2% |
| Sanofi SAN.PA | $113B | +14% | +15% | 27% | 2.6× | -5.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MAZE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +32.1% | +0.6% | highest of 21 |
| 6-month return | +29.2% | -8.7% | 4th highest of 21 |
| Distance from 52-week high | -36.3% | -27.2% | 5th lowest of 21 |
| Revenue growth (TTM) | +700.0% | +10.9% | highest of 21 |
| Operating margin | -728.1% | 17.3% | lowest of 21 |
| EV / Sales | 77.4× | 4.8× | most expensive of 21 |
| ROIC minus cost of capital | -127.0 pp | -0.0 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | 77.4× | n/a | n/a |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 4.4× | 6.0% | +29.1% |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.89B | -18% | -1% | 8% | 2.3× | 0.4% | -0.2% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | 1.1× | 11.9% | +32.4% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 7.9× | 29.3% | +15.7% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 6.4× | 20.4% | +6.2% |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 1.4× | -10.9% | +40.3% |
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 5.5× | 11.2% | +2.4% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 11.9× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 3.5× | -0.5% | +16.7% |
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 0.3× | -9.4% | +4.2% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 11.0× | n/a | n/a |
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 1.9× | -5.8% | +7.4% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 13.0× | 36.8% | -15.1% |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 5.8× | 24.7% | +20.9% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 19.2× | 14.0% | -11.0% |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 2.0× | n/a | n/a |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 0.7× | 3.7% | +7.8% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 11.1× | 38.5% | +9.2% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 5.2× | 9.1% | +9.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 2.4× | 25.0% | +6.5% |